- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00043862
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) ((SCLC))
May 30, 2017 updated by: GlaxoSmithKline
A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
This study will gather information on the effectiveness and safety of a treatment program for small cell lung cancer (SCLC) that uses an FDA approved chemotherapy combination, radiation therapy, and an oral investigational drug that may enhance the effects of radiation therapy.
Study patients will receive two additional courses of the standard chemotherapy combination after completing radiation therapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85013 - 4496
- GSK Investigational Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- GSK Investigational Site
-
-
California
-
Bakersfield, California, United States, 93309
- GSK Investigational Site
-
Fountain Valley, California, United States, 92708
- GSK Investigational Site
-
Los Angeles, California, United States, 90057
- GSK Investigational Site
-
-
Florida
-
Gainesville, Florida, United States, 32610
- GSK Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- GSK Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536-0098
- GSK Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- GSK Investigational Site
-
New Orleans, Louisiana, United States, 70121
- GSK Investigational Site
-
Shreveport, Louisiana, United States, 71103
- GSK Investigational Site
-
-
Maine
-
Scarborough, Maine, United States, 04074
- GSK Investigational Site
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01107
- GSK Investigational Site
-
-
Minnesota
-
Duluth, Minnesota, United States, 55805
- GSK Investigational Site
-
Minneapolis, Minnesota, United States, 55455
- GSK Investigational Site
-
Robbinsdale, Minnesota, United States, 55422
- GSK Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- GSK Investigational Site
-
-
Montana
-
St. Louis, Montana, United States, 63110
- GSK Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- GSK Investigational Site
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27609
- GSK Investigational Site
-
-
Ohio
-
Akron, Ohio, United States, 44304
- GSK Investigational Site
-
Cincinnati, Ohio, United States, 45236
- GSK Investigational Site
-
Cleveland, Ohio, United States, 44106
- GSK Investigational Site
-
Toledo, Ohio, United States, 43614-5809
- GSK Investigational Site
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- GSK Investigational Site
-
San Antonio, Texas, United States, 78229
- GSK Investigational Site
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54301
- GSK Investigational Site
-
La Crosse, Wisconsin, United States, 54601
- GSK Investigational Site
-
Madison, Wisconsin, United States, 53792
- GSK Investigational Site
-
Milwaukee, Wisconsin, United States, 53215
- GSK Investigational Site
-
Wausau, Wisconsin, United States, 54401
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must have newly diagnosed, limited stage SCLC (small cell lung cancer), with no prior radiotherapy. Patients are allowed to have had a resection or biopsy.
- Women of reproductive potential must have a negative serum pregnancy test at the study screening visit.
- Patients must give written informed consent to participate in the study.
- Patients must be able to take oral medication.
- Patients should be completely recovered from recent surgery.
- Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function.
- Patients must be evaluated by the radiation oncologist prior to study entry.
Exclusion Criteria:
- Extensive Stage SCLC.
- Women who are pregnant or lactating.
- Use of an investigational drug within 30 days prior to the first dose of study medication.
- Any medically/clinically significant active infection.
- Symptoms of the SCLC spreading to the brain.
- Patients with limited stage SCLC who have undergone complete resection with no measurable disease prior to starting chemotherapy.
- Severe medical problems, unrelated to SCLC, that would limit the patient's full ability to follow all study rules and procedures, or that would expose the patient to extreme risk.
- Other ongoing, immunotherapy or radiotherapy being administered at the time as study participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Response rate
|
Secondary Outcome Measures
Outcome Measure |
---|
Time to Progression, response duration, survival, quantitative and qualitative assessment of tolerability
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2002
Primary Completion (Actual)
November 1, 2005
Study Registration Dates
First Submitted
August 14, 2002
First Submitted That Met QC Criteria
August 14, 2002
First Posted (Estimate)
August 15, 2002
Study Record Updates
Last Update Posted (Actual)
May 31, 2017
Last Update Submitted That Met QC Criteria
May 30, 2017
Last Verified
March 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Topotecan
Other Study ID Numbers
- 104864/535
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Cancer
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedTobacco Use Disorder | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB...United States
-
Washington University School of MedicineMerck Sharp & Dohme LLCWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small Cell Lung Extensive Stage
-
Shanghai Chest HospitalRecruitingSmall Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer, Combined TypeChina
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
Clinical Trials on topotecan
-
Targeted Therapy Technologies, LLCActive, not recruiting
-
The Hospital for Sick ChildrenRecruiting
-
Michael Vogelbaum, MD, PhDInfuseon Therapeutics, Inc.Withdrawn
-
Hospital JP GarrahanHospital San Juan de Dios, SantiagoActive, not recruitingUnilateral RetinoblastomaArgentina
-
GlaxoSmithKlineCompletedEndometrial Cancer | Neoplasms, EndometrialUnited States, Canada, Hungary
-
Gachon University Gil Medical CenterUnknownLung Cancer | Refractory to ChemotherapyKorea, Republic of
-
GlaxoSmithKlineCompletedLung Cancer, Small CellUnited States, Netherlands
-
GlaxoSmithKlineCompletedLung Cancer, Small CellBulgaria, Hungary, Russian Federation, Netherlands, Ukraine, United Kingdom
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited States